Results 211 to 220 of about 5,903 (227)

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

British Journal of Clinical Pharmacology, 2015
Emilio Clementi, Manuela Gariboldi, Claudia Maggi   +2 more
exaly  

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

International Journal of Cancer, 2015
Gianmaria Miolo, Erika Cecchin, Angela Buonadonna   +2 more
exaly  

A novel access to 4-fluoropyrimidines from α-chlro-α′-trifluoromethylketones

Tetrahedron Letters, 1991
Guillaume de Nanteuil
exaly  

Reduced hippocampal field potentials during administration of fluoropyrimidines in vitro

Acta Neurologica Scandinavica, 1987
J Berg-Johnsen, I A Langmoen, I A Langmoen   +2 more
exaly  

Noninvasive Studies of Fluoropyrimidines

2003
Walter Wolf, Cary A. Presant, Victor Waluch   +2 more
openaire   +1 more source

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells

International Journal of Cancer, 2009
Melissa J LaBonte, Peter M Wilson
exaly  

Process for the preparation of 5-fluoropyrimidines

1992
BIELEFELDT DIETMAR DR, BRADEN RUDOLF DR
openaire   +3 more sources

FLUOROPYRIMIDINE-INDUCED CARDIOTOXICITY

Journal of the American College of Cardiology
Vishnu Bharani, Taylor Tso, Ali Naqvi
openaire   +1 more source

Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT

Tumori, 1999
Luigi Celio, Michele Del Vecchio, Giuseppe Procopio   +2 more
exaly  

Fluoropyrimidines in Cancer Therapy

2002
openaire   +1 more source